Abstract: The aim of this study is to evaluate the effects of lumbrokinase on hyperfibrinogenemia.Patients with hyperfibrinogenemia were orally ad ministered lum brokinase six tablets per day for three weeks.Seru m fibrinogen level was examined before and after treatment. Compared with the control groups which were given antilipemia or (and) antiplatelet aggregation drugs, serum fibrinogen inlumbrokinase treated group significantly decreased two weeks after treatment in a time related manner 〔Before treatment (5.34 ±0.89) g/L,two weeks aftertreatment (4.33 ±1.09) g/L,three weeks after treatment (3.71 ±0.48) g/L〕. These results showed that lumbrokinase could relieve hyperfibrinogenemia,therefore the formation of thrombi would be decreased.Lum brokinase which had less side effects could be considered as a preventive drug of coronary atherogenesis disease.

Key words: coronary atherogenesis disease (CAD), hyperfibrinogenemia, lu mbrokinase capsule